Supplementary material S1

Characterization of resistance in Gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis

Mário Gajdács [1]*, Zoltán Bátori[2], Marianna Ábrók[3], Andrea Lázár[3], Katalin Burián[3,4]

[1] Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged; 6720 Szeged, Eötvös utca 6., Hungary
[2] Department of Ecology, Faculty of Sciences, University of Szeged; 6726 Szeged, Közép fasor 52., Hungary; zbatory@gmail.com (Z.B.)
[3] Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged; 6725 Szeged, Semmelweis utca 6., Hungary; abrok.marianna@med.u-szeged.hu (M.A.), lazar.andrea@med.u-szeged.hu (A.L.)
[4] Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged; 6720 Szeged, Dóm tér 10., Hungary; burian.katalin@med.u-szeged.hu (K.B.)

* Correspondence: gajdacs.mario@pharm.u-szeged.hu; Tel: +36-62-341-330 (M.G.)

Abbreviation list: CES: *Citrobacter-Enterobacter-Serratia;* **DTR:** difficult-to-treat resistance; **mDTR:** modified difficult-to-treat resistance; **mcDTR:** modified difficult-to-treat resistance for *Escherichia coli*; **MDR:** multidrug-resistance; **n.s.:** not significant; **NFGNB:** non-fermenting Gram-negative bacteria; **PDR:** pandrug resistance; **SXT:** sulfamethoxazole-trimethoprim; **UDR:** usual drug resistance; **Wt:** wild-type; **XDR:** extensive drug resistance

Supplementary Table S1. Distribution of *Escherichia coli* isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	39.4%	34.1%	n.s.
UDR	60.6%	55.9%	n.s.
mDTR	0.8%	2.2%	p=0.043
mcDTR	0.6%	1.9%	p=0.04
MDR	0.2%	3.4%	p=0.018
DTR	0.01%	0.01%	n.s.
XDR	0%	0%	-
PDR	0%	0%	-
Highest ratio of resistant isolates for:	Ciprofloxacin	Ciprofloxacin	-

Supplementary material S1

Supplementary Table S2. Distribution of *Klebsiella* spp. isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	40.4%	45.7%	n.s.
UDR	59.6%	54.3%	n.s.
mDTR	0.4%	5.9%	p=0.011
MDR	0.3%	2.7%	p=0.028
DTR	0.2%	0.3%	n.s.
XDR	0.1%	0.1%	n.s.
PDR	0%	0%	-
Highest ratio of resistant isolates for:	Ciprofloxacin	SXT	-

Supplementary Table S3. Distribution of *Citrobacter-Enterobacter-Serratia (CES)* isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	14.0%	10.1%	n.s.
UDR	86.0%	89.9%	n.s.
mDTR	5.5%	17.0%	p=0.009
MDR	2.0%	8.3%	p=0.016
DTR	1.2%	1.9%	n.s.
XDR	0%	0.2%	n.s.
PDR	0%	0%	-
Highest ratio of resistant isolates for:	Ciprofloxacin	SXT	-

Supplementary Table S4. Distribution of *Proteus-Providencia-Morganella* isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	31.8%	22.2%	p=0.036
UDR	68.2%	77.8%	p=0.034
mDTR	13.5%	22.9%	p=0.02
MDR	7.6%	10.3%	p=0.047
DTR	0%	0.2%	n.s.
XDR	0%	0%	n.s.
PDR	0%	0%	-
Highest ratio of resistant isolates for:	SXT	SXT	-

Supplementary material S1

Supplementary Table S5. Distribution of *Pseudomonas aeruginosa* isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	52.6%	45.0%	n.s.
UDR	47.3%	55.0%	n.s.
MDR	6.8%	11.4%	p=0.028
DTR	5.3%	8.6%	p=0.042
XDR	0.8%	2.9%	p=0.049
PDR	0%	0%	-
Highest ratio of resistant isolates	Ciprofloxacin	Levofloxacin	-

Supplementary Table S6. Distribution of *Acinetobacter* spp. isolates among different resistance categories, 2008-2017

Resistance category	Outpatient isolates	Inpatient isolates	Statistics
Wt/susceptible	45.5%	11.1%	p<0.001
UDR	54.5%	88.9%	p<0.001
mDTR	11.4%	22.6%	p=0.018
MDR	7.2%	13.3%	p=0.02
DTR	5.0%	11.7%	p=0.024
XDR	2.6%	8.8%	p=0.036
PDR	0%	0%	-
Highest ratio of resistant isolates	SXT	SXT	-